Clinical Data Demonstrates That LYSTEDA Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB

SAN FRANCISCO, May 19 /PRNewswire/ — Five presentations
reporting the results of two placebo-controlled clinical trials
evaluating Ferring Pharmaceuticals’ LYSTEDA™ (tranexamic
acid) tablets, a novel, first-in-class, non-hormonal therapy
indicated for treatment of women with cyclic heavy menstrual
bleeding (HMB), were presented at The American College of
Obstetricians and Gynecologists 58th Annual Clinical Meeting in
San Francisco, May 15-19, 2010.  It is estimated that
up to 22 million women suffer from HMB in the U.S.(1),(2)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100510/NY01272LOGO
)

LYSTEDA oral tablets received approval on November 13, 2009 following a Priority
Review by the U.S. Food and Drug Administration (FDA).
 Ferring recently signed an agreement with Xanodyne
Pharmaceuticals, Inc. that will expand its Women’s Health product
portfolio with the acquisition of the global rights to LYSTEDA,
which the company will initially market in the U.S.

“We are extremely pleased by the substantial clinical evidence
supporting LYSTEDA as a new therapy for heavy menstrual bleeding.
 LYSTEDA was shown to significantly reduce menstrual blood
loss in women suffering from cyclic heavy menstrual bleeding,” said
Andrea Lukes, MD, lead study
investigator, Carolina Women‘s
Research and Wellness Center.  “As a result of taking this new
treatment, most women in the trial said t

‘/>”/>

SOURCE